New Triple-Action antibody takes on tough blood cancers
NCT ID NCT05652335
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 28 times
Summary
This early-phase study tests an experimental drug called JNJ-79635322, a trispecific antibody designed to attack cancer cells in multiple ways. It is for people with multiple myeloma or AL amyloidosis that has returned or not responded to prior treatments. The main goals are to find a safe dose and check for side effects in about 180 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Lyon Sud
RECRUITINGPierre-Bénite, 69495, France
-
CHU Nantes
RECRUITINGNantes, 44093, France
-
CHU de Liege
RECRUITINGLiège, 4000, Belgium
-
Chu Rennes Hopital Pontchaillou
COMPLETEDRennes, 35000, France
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
City of Hope Orange County Lennar Foundation Cancer Center
RECRUITINGIrvine, California, 92618, United States
-
Clinica Univ. de Navarra
RECRUITINGPamplona, 31008, Spain
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
Hosp Clinic de Barcelona
RECRUITINGBarcelona, 08036, Spain
-
Hosp Clinico Univ de Salamanca
RECRUITINGSalamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
Hosp. Univ. Germans Trias I Pujol
RECRUITINGBadalona, 08916, Spain
-
Icahn School of Medicine at Mt. Sinai
RECRUITINGNew York, New York, 10029, United States
-
Institut Claudius Regaud
RECRUITINGToulouse, 31100, France
-
Japanese Red Cross Medical Center
ACTIVE_NOT_RECRUITINGShibuya City, 150-8935, Japan
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28001, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Osaka University Hospital
ACTIVE_NOT_RECRUITINGSuita-shi, 565-0871, Japan
-
Royal Marsden Hospital
RECRUITINGSutton, SM2 5PT, United Kingdom
-
The Cancer Institute Hospital of JFCR
COMPLETEDTokyo, 135-8550, Japan
-
UMC Utrecht
RECRUITINGUtrecht, 3584 CX, Netherlands
-
UZ Antwerpen
RECRUITINGEdegem, 2650, Belgium
-
UZ Gent
RECRUITINGGhent, 9000, Belgium
-
Universitair Medisch Centrum Groningen
RECRUITINGGroningen, 9713 GZ, Netherlands
-
University College Hospital
RECRUITINGLondon, W1T 7HA, United Kingdom
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
-
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
VUMC Amsterdam
RECRUITINGAmsterdam, 1081 HV, Netherlands
Conditions
Explore the condition pages connected to this study.